Treatment with inhaled glucocorticosteroids via dry powder inhalers seems to be associated with a higher systemic effect than treatment via metered dose inhalers used with a spacer device.'4 This is often assumed to be due to higher oropharyngeal deposition of drug with dry powder treatment but the bioavailability of budesonide from the oropharynx after swallowing is rather low: about 13%.5 It seems unlikely therefore that systemic absorption of budesonide from the oropharynx alone would cause the difference in systemic activity detected in children at daily doses as low as 400 [ig (S Pedersen, 0 R Hansen, unpublished) .
In an earlier study, plasma concentrations of budesonide after inhalation via Turbuhaler (Astra) were markedly higher than the concentrations obtained after inhalation via Nebuhaler (Astra) (S Pedersen et al, unpublished), even when absorption of swallowed drug was blocked by activated charcoal. We concluded that higher drug deposition in the lungs was [2] [3] [4] [5] [6] [7] (1-1) 2 5 (1-0) FEV, (1) 
FEF25-75%(I/sec) (-14-00 to 7-18) Evening PEFR (1/min) 297 In studies comparing inhalation devices, it is important that patients are not overtreated at study entry and, therefore, on the upper flat part of the dose-response curve. To avoid this, only patients who had recently demonstrated a need for their prescribed dose of budesonide were included. The tendency for asthma symptoms and pulmonary function to improve throughout the study period suggested that the children were not overtreated at entry. Furthermore, the rather frequent use of rescue terbutaline sulphate during the run-in and the treatment period is another indication that we were successful in selecting an appropriate patient population.
The steady improvement in pulmonary function throughout the study could have been due to an improvement in compliance, which is common during clinical studies, or to the fact that the study was conducted between January and July; spring and early summer are normally 'good periods' for children with asthma in Denmark.
Before the study, we believed that all of the 241 children who participated in the evaluation period would be sensitive to a reduction in their dose of inhaled budesonide. The evaluation period, however, was only three weeks long and most of the 115 children whose asthma did not deteriorate experienced a deterioration later when they continued on the reduced budesonide dose via Nebuhaler. This observation emphasises the importance of performing studies with inhaled corticosteroids for a sufficient duration. The treatment period in the present study was about three times longer than the period shown to cause a previous deterioration in the asthma condition for all participants. Therefore, we believe that the observation period was adequate to detect a difference in effect between the two inhalers. Although the recruitment of children for the study took place during winter, viral infections were rare and never the cause of deteriorations in asthma control during the evaluation period in the children who were included in the study. Therefore 
